Replimune Group Inc (REPL) stock saw a modest uptick, ending the day at $11.85 which represents a slight increase of $1.71 or 16.86% from the prior close of $10.14. The stock opened at $12.6 and ...
Replimune Group Inc has established itself as a leader in the field of oncolytic immunotherapy, with a wholly-owned pipeline and advanced manufacturing facilities. The company's primary focus is ...
Barclays (LON:BARC) reaffirmed its positive stance on Replimune Group (NASDAQ:REPL), maintaining an Overweight rating and a $17.00 price target, representing significant upside from the current price ...
Results that may be inaccessible to you are currently showing.